Stereotactic body radiotherapy is utilized to treat lung cancer. The mechanism of tumor response to high-dose radiotherapy (HDRT) is controversial, with competing hypotheses of increased direct tumor cell killing versus indirect effects on stroma including endothelial cells. Here we used dual recombinase technology in a primary murine lung cancer model to test whether tumor cells or endothelial cells are critical HDRT targets. Lenti-Cre deleted one or two copies of ataxia-telangiectasia mutated gene (Atm; KPA FL/þ or KPA FL/FL ), whereas adeno-FlpO-infected mice expressed Cre in endothelial cells to delete one or both copies of Atm (KPVA FL/þ or KPVA FL/FL ) to modify tumor cell or endothelial cell radiosensitivity, respectively. Deletion of Atm in either tumor cells or endothelial cells had no impact on tumor growth in the absence of radiation.
Introduction
Lung cancer is the leading cause of cancer mortality in the United States and presents a significant therapeutic challenge (1) . Radiotherapy is commonly utilized in the treatment of lung cancer, but therapeutic advances are needed to improve outcomes. Stereotactic body radiotherapy (SBRT) is a recent innovation that utilizes precise localization to deliver a high dose of radiation (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Gy) during each treatment session to the tumor, while sparing surrounding normal tissue. Although we and a number of other investigators have observed vascular dysfunction in tumors after a single high dose of radiation (2, 3) , whether this impairment contributes to the effectiveness of SBRT remains controversial. It is conceivable that the increased dose per fraction of SBRT simply kills more tumor cells (4) . Alternatively, the efficacy of high-dose radiotherapy (HDRT) may be a consequence of injury to the supporting stromal tissue including endothelial cells, which results in vascular dysfunction and may impair tumor cell survival (5, 6) . This hypothesis of indirect cell killing is largely supported by in vitro radiation survival assays, which predict that much larger radiation doses than those routinely delivered in the clinic are required for eradication of human tumor cells (7) . In addition, xenografts implanted into mice with defects in the ceramide-mediated endothelial cell apoptosis pathway were resistant to large doses of radiation, suggesting that endothelial cell death was a major determinant of the tumor response to radiotherapy (8) . However, the patterns of vascularization in subcutaneous implants may differ from that in primary cancers, which may affect perfusion, oxygenation, and radiation response (9) .
Genetically engineered mouse models (GEMM) allow the study of primary cancers arising in the native microenvironment of immunocompetent mice. Our laboratory generated novel genetically engineered mice to enable dual recombinase technology for temporal and spatial control of different somatic mutations in tumor cells and endothelial cells in mice with primary cancers (10) . In this model, we selectively deleted the ataxiatelangiectasia mutated (Atm) gene to radiosensitize different cellular targets. ATM is an apical kinase critical in the DNA damage response to radiotherapy (11) and patients with inherited mutations in both ATM alleles are hypersensitive to ionizing radiation (12) . In a primary mouse model of sarcoma (13) , we employed dual recombinase technology to delete Atm in endothelial cells, which delayed tumor growth after 20 Gy, but was not sufficient to improve rates of local control following higher doses of radiotherapy (14, 15) . In contrast, Atm deletion in the sarcoma cells led to increased local control, suggesting tumor cells, rather than endothelial cells, were the critical targets of high-dose radiotherapy. Whether these results extend beyond sarcomas has not been evaluated.
Here, we use dual recombinase technology in a primary mouse model of non-small cell lung cancer to delete Atm in either endothelial cells or tumor cells to investigate the role of distinct cell types in mediating the response of lung tumors to a large, single dose of radiotherapy.
Materials and Methods

Mice strains and lung tumor initiation
All animal studies were performed in accordance with protocols approved by the Duke University Institutional Animal Care and Use Committee (Durham, NC). Mouse strains used in this study have been described previously (10, (16) (17) (18) (19) (20) (21) . All mice were maintained on a mixed genetic background. The FSF-Kras G12D/þ ; p53 FRT/FRT (KP FRT ) strain was used for dual recombinase experiments investigating the role of endothelial cells in tumor response to radiation, while the LSL-Kras G12D/þ ; p53 FL/FL (KP FL ) strain was used to directly modify tumor cell radiosensitivity. To investigate the effectiveness of VE-Cadherin-Cre-mediated recombination in the lung, VE-Cadherin-Cre mice were crossed with mice harboring the Cre-reporter Rosa-26-LSL-Tomato.
To activate the expression of oncogenic Kras G12D and delete both p53 alleles in the lung epithelia of KP FRT mice, an adenovirusexpressing FlpO recombinase [Ad5CMVFlpO (cat# VVC-U of Iowa-530), University of Iowa Viral Vector Core Facility, Iowa City, IA] was delivered intranasally to mice between 6 and 12 weeks of age as described previously (10) . To activate the expression of oncogenic Kras G12D and delete both p53 alleles in the lung epithelia of KP FL mice, a lentivirus-expressing Cre recombinase [FIV 3.2CMVCre-eGFP VSVG (cat# VVC-U of Iowa-229), University of Iowa Viral Vector Core Facility, Iowa City, IA] was delivered intranasally to mice between 6 and 12 weeks of age by adapting a published protocol (22) . A total of 5 Â 10 5 pfu/mL lentivirus (25 mL)was diluted in 725 mL minimal essential media and 30 mL was delivered via intranasal inhalation to each mouse. Mice were then given a 30 mL chaser of media.
The KP FL mice were crossed to mice in which one (Atm FL/þ ) or both copies of Atm (Atm FL/FL ) were flanked by loxP sites (subsequently referred to as KPA mice). Thus, lentiviral delivery of Cre not only activates the expression of oncogenic Kras G12D and deletes both p53 alleles in the lung epithelial cells, but also deletes one or both alleles of Atm (Table 1 ; Fig. 1A ). To delete Atm specifically in endothelial cells, KP FRT mice were crossed to Atm FL/þ or Atm FL/FL mice and VE-Cadherin-Cre mice (subsequently referred to as KPVA). Thus, Cre-mediated recombination is confined to cells expressing the endothelial cell-specific promoter VE-cadherin (23) . In KPVA mice, therefore, expression of FlpO recombinase in lung epithelial cells activates expression of oncogenic Kras G12D and deletes both p53 alleles while Cre recombinase deletes one or two copies of Atm specifically in endothelial cells ( Table 2 ; Fig. 1B ). For all experiments, Atm FL/FL mice, in which Cre deletes both copies of Atm in either the tumor cells or endothelium, represented the experimental group, while Atm FL/þ littermates that retained a wild-type copy of Atm were used as controls.
Micro-CT imaging and tumor growth assessment
Mice were imaged for tumor development by serial micro-CT at 2-week intervals beginning 8 weeks postinfection (Fig. 1C and D). The XRAD225 Cx (Precision X-Ray, Inc.) small-animal image-guided irradiator was used for serial micro-CT and radiotherapy. During CT image acquisition and radiotherapy, mice were placed in a prone position and anesthetized with isoflurane via a nose cone delivery system. Mice were breathing freely during image acquisition, thus tumor volumes represented an internal target volume that integrated changes over the respiratory cycle.
For CT acquisition to image the lungs, 40 kVP, 2.5 mA X-rays were used with a 2-mm Al filter. Images generated from CT reconstruction were analyzed using the Amira 3D Visualization and Analysis Software Suite (FEI, Thermo Fisher Scientific) to calculate tumor volumes (24) . Lung tumors were identified in each mouse, and only tumors that demonstrated growth between scans were selected as target lesions for continued growth assessment. Each lesion was contoured to calculate the tumor volume. In most mice, multiple target lesions were identified. Tumor contouring was performed by an individual blinded to treatment and mouse genotype. When a target lesion demonstrated growth over a 2 week period, the CT scan documenting tumor growth would serve as a reference baseline CT scan for growth assessment. Given the variability of tumor development between cohorts, the baseline scan would vary ranging from 10 to 14 weeks postinfection. For a given genotype, mice were randomly allocated to observation or irradiation and were stratified by tumor number and size. Target lesion volume was subsequently measured every 2 weeks and normalized to the volume at baseline to calculate fold changes in tumor volume. New tumors that were detected after the baseline scan were excluded from analysis. Target lesions obscured by disease progression or other anatomic changes were also excluded.
Radiation treatment
Therapeutic lung irradiation was performed using a smallanimal image-guided irradiator (described above). The radiation field was centered mid-thorax via fluoroscopy with 40 kVp, 2.5 mA X-rays using a 2-mm Al filter. Mice were irradiated with parallel-opposed anterior and posterior fields to the whole thorax using a collimator with a 20 mm Â 20 mm field size. A single fraction of 15 Gy was prescribed to midplane with 225 kVp, 13 mA X-rays using a 0.3-mm Cu filter with an average dose rate of 300 cGy/minute. Machine quality assurance was maintained by the Radiation Safety Division at Duke University (Durham, NC). 
Cell culture and clonogenic survival
Lung adenocarcinoma cell lines were generated by homogenizing and digesting primary lung tumors from KPA FL/þ or KPA FL/FL mice with 200 U/mL type I collagenase (Gibco) and 2.4 U/mL dispase (Gibco) dissolved in PBS for 1 hour at 37 C. The suspension was then filtered and red blood cells were lysed with ACK lysing buffer (Lonza). Cells were cultured in DMEM (Gibco) with 4.5 g/L glucose and pyruvate supplemented with 10% FBS and 1% penicillin/streptomycin. To improve culture success rate, cellular suspensions were plated on mouse embryonic fibroblasts inactivated by irradiation (Gibco) and 10 mmol/L of the ROCK inhibitor Y-27632 (Sigma Aldrich) was added to the culture media. Primary tumor cell lines were used at an early passage (typically 4-6) after stromal cell contamination had been depleted, which was confirmed by PCR genotyping of genomic DNA. Mycoplasma testing was not performed. For clonogenic survival assays, cells were plated in triplicate and left overnight to adhere before irradiation with an X-RAD 320 Biological Irradiator (Precision X-Ray, Inc.). Cells were placed 50 cm from the radiation source and irradiated with a dose rate of 1.96 Gy/minute using 320 kVp, 10 mA X-rays and a 2-mm Al filter. The media was replaced 24 hours after IR treatment with fresh media. Cells were allowed to grow for 7 days until they were fixed with 70% ethanol and then stained with Coomassie Brilliant Blue (Bio-Rad). Cell populations with at least 50 cells were counted as a colony and surviving fractions were determined relative to unirradiated controls.
Endothelial cell isolation
Endothelial cells were isolated from lung tissue in KPVA FL/þ and KPVA FL/FL mice using a similar digestion protocol as above. Endothelial cells were isolated by FACS (Astrios, Beckman Coulter) using FITC-conjugated anti-mouse CD31 and PE-conjugated anti-mouse CD105 (eBioscience), where dead cells were excluded by 7-AAD staining (BD Biosciences). Atm mRNA was extracted directly from sorted cells and relative expression levels were measured by qRT-PCR as described below.
qRT-PCR
RNA was extracted from cell pellets with the RNAqueous-Micro Kit (Ambion) and reverse transcription performed with the iScript cDNA Synthesis Kit (Bio-Rad). qPCR was performed using TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assay Mix with probes for Atm (Mm01177459_m1) and Gapdh (Mm99999915_g1) as a reference (Applied Biosystems). Samples were run in triplicate on the iQ5 qPCR system (Bio-Rad), averaged, and reported as relative concentrations based on the average of samples containing a wild-type copy of Atm.
PCR genotyping
To examine recombination of floxed alleles of Atm, the following primers were used: sense 5 0 -TGAGTTCAAATCCCAGGAGC-CAG-3 0 and antisense 5 0 -CTTCCCCTGTTCAAAAGCCACTC-3 0 (cycling at 94 C for 30 seconds, 57 C for 30 seconds, and 72 C for 30 seconds). To detect unrecombined ATM FL alleles, the following primers were used: sense 5 0 -GGGCTACGAAATGAGAC-ACACAC-3 0 and antisense 5 0 -CTTCCCCTGTTCAAAAGCCACTC-3 0 (cycling at 94 C for 30 seconds, 60 C for 30 seconds, and 72 C for 30 seconds).
Histologic analysis
Histologic analysis and immunofluorescence (IF) of the lung adenocarcinomas were performed on frozen tissue sections. Tissue samples were fixed in 4% paraformaldehyde for 2 hours and subsequently transferred to a 30% sucrose solution overnight. The tissue was then embedded directly in OCT compound (Sakura Fintek) by snap freezing in a dry ice/isopentane slurry and stored at À80 C until sectioning. Ten-micron-thick sections were cut prior to IF staining. For endothelial cell staining, the primary antibody used was rat anti-mouse CD31 (diluted 1:250; BD Biosciences). The secondary antibody used was Alexa Fluor 488-conjugated donkey anti-rat IgG (diluted 1:500; Invitrogen). Nuclear staining was performed using Hoechst 33342 (10 mmol/L; Sigma-Aldrich). Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was performed with the InSitu Cell Death Detection Kit, TMR Red (Roche), according to the manufacturer's instructions. Images were acquired with a Leica DFC340 FX fluorescence microscope (Leica Microsystems) using Leica Suite Software (Leica Microsystems). ImageJ (NIH, Bethesda, MD) was used for quantification of CD31-TUNEL double-positive cells by an observer blinded to mouse genotype and treatment regimen. Each data point represents the average of 7-8 randomly selected 200 Â magnification fields per mouse. A similar approach was used for quantification of CD31-Tomato colocalization.
Statistical analysis
Experimental cohort numbers were determined from previous observations. On the basis of the initial effect size, 141 tumors would be necessary to detect a significant difference in growth delay between KPVA genotypes with an alpha of 0.05, 80% power, and 30% dropout rate 6 weeks following the baseline scan. A typical mouse would develop approximately 6 tumors that could be monitored for growth, thus 24 mice would be necessary. For KPA genotypes, the initial experiments to determine effect size showed a significant difference. Therefore, a formal power calculation was not performed. The GraphPad Prism (v7.0) software was used to fit growth curves based on tumor volumes in each treatment cohort. Individual data points on growth curves represent the mean AE SEM. Comparisons between genotypes were analyzed using an unpaired t test with an alpha of 0.05 designated as significant. Two-way ANOVA was utilized to compare the interaction between genotype and radiation dose or timepoint.
Results
Endothelial cell-specific deletion of Atm does not impact primary lung tumor development or growth
To evaluate the efficiency of deleting the Atm FL allele in endothelial cells with the VE-Cadherin Cre promoter, we isolated lung endothelial cells from KPVA FL/þ and KPVA FL/FL mice and quantified Atm mRNA. Compared with the endothelial cells from KPVA FL/þ controls, those from KPVA FL/FL mice had significantly less Atm mRNA ( Fig. 2A ). Residual Atm expression in the sorted cells isolated from KPVA FL/FL mice may be a result of several factors. FACS endothelial purity was estimated to be 93% (Supplementary Fig. S1A ), thus a small proportion of nonendothelial cells reduced the apparent effectiveness of Atm deletion in the qRT-PCR analysis. Another possible explanation for residual Atm expression is that the VE-Cadherin-Cre mice do not express Cre uniformly in all lung endothelial cells as we previously showed in the heart (23) . To quantify the expression of Cre in the lung endothelium, we crossed the VE-Cadherin-Cre mice to mice expressing a Cre-activatable red fluorescent protein (Tomato) allele. The lungs were harvested and sections were stained for CD31 to label endothelial cells and IF was performed to assess colocaliztion of Tomato with CD31 ( Fig. 2B ). Approximately 80% of the CD31-expressing cells were positive for Tomato (Fig. 2C) . Thus, a subset of lung endothelial cells do not express Cre recombinase, which further contributes to residual Atm expression in the flow-sorted endothelial cells. Endothelial density in the lungs as assessed by CD31 fractional area was similar between KPVA FL/FL and KPVA FL/þ mice (Fig. 2D) .
To determine whether Atm deletion in the endothelial cells affected tumor growth, tumors from both genotypes were subjected to serial micro-CT scanning every 2 weeks starting 8 weeks postinfection and then contoured for tumor growth analysis. There was no difference in the number of tumors per mouse or tumor volume between genotypes ( Supplementary Fig. S1B and S1C, respectively). In these observational cohorts, fold tumor volume at 2 and 4 weeks increased by 1.8 AE 0.1 and 3.8 AE 0.5 in the KPVA FL/þ group (n ¼ 43 tumors, 8 mice) and 2.1 AE 0.1 and 4.4 AE 0.4 in the KPVA FL/FL group (n ¼ 67 tumors, 13 mice), respectively. Tumors reached approximately 6-fold growth at 6 weeks, with approximately half of the tumors being excluded because of progression or death of the mouse. Differences in growth rate were not statistically significant, suggesting that endothelial cell-specific Atm deletion does not influence primary lung tumor growth ( Fig. 2E and F) .
Endothelial cell-specific deletion of Atm increases radiationinduced endothelial cell death, but does not radiosensitize lung tumors
We next investigated whether endothelial cell-specific deletion of Atm could modulate the radiosensitivity of primary lung adenocarcinomas. CD31 and TUNEL IF double staining 24 hours after irradiation revealed that the deletion of Atm increased endothelial cell death in KPVA FL/FL mice compared with controls ( Figs. 3A and B ). Furthermore, a significant increase in the total number of TUNEL-positive cells suggests that increased endothelial cell death can trigger death of neighboring cells (Fig. 3C ). Increased endothelial cell death in KPVA FL/FL mice, however did not translate to improved tumor growth delay 2-6 weeks following radiation (Fig. 3D and E) . For the irradiated mice at 2, 4, and 6 weeks, tumors increased by a factor of 1. 
Atm deletion in lung tumor cells leads to radiosensitization
To assess the role of tumor parenchymal cells in radiationinduced growth delay, we also examined whether the deletion of Atm in tumor cells could modulate the radiation response of primary lung adenocarcinomas. qRT-PCR to confirm Atm deletion in KPA tumor cell lines revealed significantly less Atm mRNA levels from KPA FL/FL mice compared with controls ( Fig. 4A) . Recombination of ATM FL alleles was verified with PCR ( Supplementary  Fig. S1D ). Loss of Atm in the lung tumor cells did not impact the number of tumors per mouse or tumor volume at baseline ( Supplementary Fig. S1E and S1F ). In the absence of radiation, tumor growth rate did not differ between genotypes (Figs. 4B and C). Relative tumor volume at 2, 4, and 6 weeks for the KPA FL/þ mice was 1.7 AE 0.1, 2.9 AE 0.3, and 4.6 AE 0.8 (n ¼ 22 tumors, 6 mice) and 1.7 AE 0.1, 4 AE 0.6, and 4.9 AE 0.9 (n ¼ 17 tumors, 4 mice) for the KPA FL/FL mice, respectively. No statistically significant differences were noted at any time point. However, when mice were treated with a single dose of 15Gy to the whole thorax, a significant growth delay was observed in tumors from KPA FL/FL mice (Figs. 4D and E). Relative volume for irradiated KPA FL/þ tumors (n ¼ 30 tumors, 8 mice) at 2, 4, 6, and 8 weeks was 1.7 AE 0.2, 1.8 AE 0.3, 2.9 AE 0.6, and 5.9 AE 1.4, respectively. The corresponding relative volume at the same time points for irradiated KPA FL/FL tumors (n ¼ 36 tumors, 8 mice) was 1.31 AE 0.06, 1.22 AE 0.08, 1.3 AE 0.1, and 1.40 AE 0.09 with the differences at the 6-and 8-week time points being statistically different. Radiosensitization was clearly apparent in a clonogenic survival assay of KPA cell lines, in which colony survival was significantly reduced in irradiated KPA FL/FL cells compared with controls cell lines retaining one allele of Atm (Fig. 4F) . While use of a ROCK inhibitor to establish cancer cell lines may have had an effect on tumor cell survival, an identical protocol was used for the two genotypes. Therefore, the difference in surviving fraction most likely relates to the expression of Atm.
Discussion
Endothelial cells are important stromal components for tumor growth and metastasis (25, 26) . This has driven extensive research into targeting angiogenesis with therapeutic agents. The role of endothelial cells in the response of tumors to radiation is less clear and remains an area of controversy in radiation biology (27, 28) .
A melanoma xenograft model in mice lacking Atm in endothelial cells had impaired tumor neoangiogenesis and growth (29) . The authors postulated that Atm has a protective role against reactive oxygen species (ROS), where the absence of Atm leads to excessive accumulation of ROS that suppresses angiogenesis. However, we found no difference in primary lung tumor growth or tumor vessel density in mice where 80% of lung endothelial cells lack Atm as compared with mice in which endothelial cells retained a wild-type copy of Atm. These data are consistent with our previous study showing similar growth of autochthonous sarcomas in mice regardless of Atm expression in endothelial cells (14) . Xenograft models are known to display site specific variation in vascular perfusion and hypoxia (9) , which may explain why Atm loss in endothelial cells affected xenograft tumor growth, but does not impact the growth of lung cancer or sarcomas (14) in autochthonous model systems.
Experiments in xenograft models have also suggested that endothelial cell death plays a critical role in tumor response to SBRT. For example, xenograft implants of MCA/129 fibrosarcoma and B16 melanoma tumors grown in acid-sphingomyelinase (asmase)-deficient mice were reported to be resistant to large therapeutic single-dose radiotherapy compared with wild-type controls (8) . Because asmase is abundant in endothelial cells and mediates apoptosis via the ceramide pathway, the prolonged growth delay of xenograft tumors in asmase À/À mice after HDRT was interpreted as being caused by an increase in endothelial cell death. In another study, FSaII fibrosarcoma xenografts were treated with HDRT in vivo and had reduced in vitro clonogenic survival 5 days after radiation compared with cells harvested immediately after radiation (6) . The decreased clonogenic survival was interpreted to reflect indirect tumor cell death as a consequence of vascular damage, which was proposed to play a crucial role in the response of tumors to SBRT.
To test the hypothesis that endothelial cell death plays a critical role in tumor response to SBRT in autochthonous models, we have employed dual recombinase technology, which is an innovative approach to provide spatial control over different conditional mutations in primary mouse models of cancer. To employ two recombinases in one experimental system, we first crossed mice with multiple conditional alleles together to generate KPVA FL/FL mice. Then, we used FlpO to initiate lung cancers and Cre to delete Atm specifically in endothelial cells to successfully achieve selective radiosensitization of endothelial cells in primary lung cancers. Despite enhanced radiation-induced endothelial cell death in the KPVA FL/FL tumors compared with KPVA FL/þ controls, no statistically significant difference in tumor growth delay was observed after 15 Gy of radiation. This finding suggests that endothelial cell death does not significantly impact primary lung cancer response to HDRT. In contrast, significant growth delay was only achieved with Atm deletion in the lung tumor parenchymal cells. By applying dual recombinase technology in autochthonous sarcomas in mice, we recently found that deleting Atm in the tumor cells, but not endothelial cells, enhanced local control after single HDRT (15) . Taken together, these studies indicate that in autochthonous lung cancers and sarcomas, the efficacy of SBRT is a consequence of enhanced tumor cell killing rather than increased endothelial cell death.
Although our results suggest that endothelial cell death is not a critical mechanism for tumor control after SBRT, we have observed vascular changes in primary tumors after high singledose radiotherapy. It is possible that these radiation-induced vascular changes may be insufficient to impact tumor control because of vasculogenesis from bone marrow-derived cells that can reconstitute tumor vasculature after radiotherapy (30) . It has also been reported that radiation activates VEGF expression, which can promote endothelial cell proliferation (31) . Therefore, tumors may be able to redevelop their blood supply after highdose radiotherapy.
While our results support the conclusion that radiosensitizing tumor cells will be more effective clinically than radiosensitizing endothelial cells, there are several limitations to our model system. As Atm recombination occurred in approximately 80% of lung endothelial cells, it is conceivable that approaches that enhance endothelial cell death above the 2-fold increase we observed in this system may enhance tumor growth delay after irradiation. While this model focused on endothelial cell death, other indirect mechanisms such as immune cell stimulation and infiltration may play an important role in tumor response to SBRT. It is unclear whether disrupting the vasculature would be synergistic or inhibitory to such an immune response. Our model also does not reflect how other methods of increasing treatment efficacy, such as the addition of chemotherapy concurrent to radiotherapy, would affect endothelial cells. Future studies in other primary mouse models of cancer will be needed to deter-mine if these conclusions are generalizable beyond lung cancers and sarcomas and how other treatment and host factors contribute to tumor control. Finally, a limitation of GEMMs is their relative genetic simplicity, while human tumors have a significantly greater mutational landscape (32) .
In summary, in autochthonous lung cancers in mice, Atm deletion in endothelial cells had no impact on tumor growth in the absence of radiation and no statistically significant effect on growth delay after irradiation. However, Atm deletion in the lung tumor parenchymal cells significantly enhanced growth delay following radiation. Therefore, these data indicate that tumor cells, rather than endothelial cells, are the critical targets for tumor response to single HDRT in lung cancer. These results also support efforts to bring ATM inhibitors into the clinic in combination with highly conformal radiotherapy to try to improve the outcome of lung cancer treated by radiotherapy.
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